| • The only antipsychotic agent available for TRS |
| • Highly effective for the treatment of positive symptoms |
| • More effective in reducing negative symptoms than the firstly approved typical antipsychotics |
| • Significant improvement in the life of patients diagnosed with schizophrenia |
| • Improved disorganised behaviour |
| • Treatment with clozapine leads to reductions in the number of hospitalised patients |
| • Decrease in hospital costs and overall treatment expenses |
| • Efficacy on depression |
| • Shown to reduce recurrent suicidal behaviour in subjects diagnosed with the disorder |
| • No extrapyramidal side effects (EPSEs) |
| • No tardive dyskinesia |
| • No elevation in prolactin levels |
| • Chance of relapse during clozapine therapy is less than with other antipsychotics |
